Last Update 11 Mar 26

Fair value Increased 9.52%

FENC: Single Oncology Supportive Care Asset Will Drive Future Upside Potential

Narrative Update: Fennec Pharmaceuticals

Analysts have lifted their price target on Fennec Pharmaceuticals from $14.00 to about $15.33, citing a richer revenue outlook, higher anticipated profit margins, and a willingness to apply a lower future P/E multiple. They highlight Pedmark's position as a unique, FDA approved option in oncology supportive care, with U.S. peak sales potential referenced above $300m.

Analyst Commentary

Bullish analysts are framing Fennec Pharmaceuticals as a focused bet on Pedmark, with views that center on the drug's positioning in oncology supportive care and its potential to scale within a defined niche.

Bullish Takeaways

Pedmark is viewed as a unique opportunity in oncology supportive care, as it is described as the only agent approved to reduce the risk of cisplatin induced ototoxicity. This supports a premium narrative around the asset.
Some bullish analysts reference U.S. peak sales potential north of $300m, which they see as a key driver for justifying higher valuation targets relative to current revenue contribution.
Initiation reports with positive ratings and double digit price targets, including the cited US$18 level, are interpreted as signals that the current share price does not fully reflect the commercial potential of Pedmark.
Analysts who point to a richer revenue outlook and higher anticipated profit margins link Pedmark's profile to potential operating leverage, assuming execution on commercialization stays on track.

Bearish Takeaways

Even in bullish reports, there is an implicit execution risk, as the investment case leans heavily on a single product. Any slowdown in uptake or unexpected competitive pressure could weigh on the valuation.
References to applying a lower future P/E multiple suggest some analysts are cautious about assigning a very high long term earnings multiple to a concentrated product story.
The focus on peak U.S. sales potential, rather than current sales, indicates that a meaningful part of the thesis is based on future commercial progress, which may take time and could be uneven.
Reliance on a specific supportive care indication means that growth beyond the core cisplatin induced ototoxicity setting is not clearly laid out in the commentary provided. This may limit how far some analysts are willing to stretch valuation assumptions.

What's in the News

Tampa General Hospital Cancer Institute is launching a real world study of PEDMARK in adolescent, young adult, and adult cancer patients receiving cisplatin based treatment, focused on assessing its utility in reducing ototoxicity and informing future clinical research and quality efforts (company announcement).
The study at Tampa General Hospital, in collaboration with USF Health Morsani College of Medicine, will pair clinical data with audiology monitoring to better understand how often hearing loss occurs with cisplatin treatment and how it affects long term quality of survivorship, including speech, academic performance, social development, and independence (company announcement).
New real world data on PEDMARK in adults with head and neck cancers were presented as a digital poster at the 2026 Multidisciplinary Head and Neck Cancers Symposium in Palm Desert. A retrospective review of 15 adults suggested PEDMARK could be given within a 6 hour window after cisplatin without disrupting curative intent treatment delivery (company announcement).
In that head and neck cancer review, PEDMARK was reported as well tolerated, with only isolated, self limited infusion events, no grade 3 or 4 toxicities, and feasibility assessed through timing adherence, administration setting, infusion chair time, and audiology assessments (company announcement).
PEDMARK is currently approved for pediatric patients one month of age and older with localized, non metastatic solid tumors and carries a 2A recommendation from the National Comprehensive Cancer Network for use in adolescent and young adult patients (company announcement).

Valuation Changes

Fair Value: Updated analyst fair value estimate has risen slightly from $14.00 to about $15.33 per share.
Discount Rate: The discount rate has moved up modestly from 6.80% to about 7.20%, implying a slightly higher required return in the model.
Revenue Growth: The assumed $revenue growth rate has been lifted from about 44.6% to about 53.4%, reflecting a richer $revenue outlook for the forecast period used.
Net Profit Margin: The modeled $net profit margin has increased from about 40.7% to about 44.4%, indicating higher expected profitability on projected $sales.
Future P/E: The future P/E multiple applied in the valuation has fallen meaningfully from about 12.1x to about 8.8x, signaling a more conservative earnings multiple being used.

4 views

Key Takeaways

Expanding into new patient segments and global markets is fueling strong revenue growth and increasing adoption of PEDMARK® through strategic partnerships and investments.
Positive regulatory developments and operational efficiencies are expected to improve margins, enable further product expansion, and support a move toward sustainable profitability.
Heavy reliance on a single product, facing saturation, pricing pressures, competitive threats, and high operating costs could constrain revenue growth and increase financial risk.

Catalysts

About Fennec Pharmaceuticals

Operates as a commercial stage biopharmaceutical company in the United States.What are the underlying business or industry changes driving this perspective?

The increasing prevalence of cancer due to an aging population is generating long-term demand for supportive care therapies like PEDMARK®, and Fennec's expanded market focus to include the much larger adolescent and young adult segment (AYA; ages 15–39) is now driving significant sequential revenue growth-potential for further revenue acceleration as more large oncology group accounts are penetrated and utilization deepens.
Strengthened global healthcare spending and improved access to cancer therapies, particularly with international launches (e.g., the Norgine partnership in the EU and upcoming Japan study results/partnership), position the company for meaningful global revenue expansion and cash flow improvement through milestone payments and royalties in addition to direct product sales.
Strategic investments in sales force, patient support programs, and peer-reviewed guideline endorsements (e.g., PQI for PEDMARK) are driving greater adoption and repeat usage within new and existing accounts, supporting durable top-line growth and enhancing operating leverage as commercial efficiency improves.
Ongoing positive regulatory sentiment, including orphan drug support and favorable real-world data requirements, may facilitate future label expansions or additional indications for PEDMARK®, potentially opening new revenue streams and lengthening the product's lifecycle.
Manufacturing and operational scale benefits are expected as sales grow, with anticipated second-half 2025 expense reductions and increasing topline momentum pointing to the likelihood of improving net margins and a path toward sustainable profitability.

Fennec Pharmaceuticals Earnings and Revenue Growth

Fennec Pharmaceuticals Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Fennec Pharmaceuticals's revenue will grow by 44.6% annually over the next 3 years.
Analysts assume that profit margins will increase from -36.1% today to 40.7% in 3 years time.
Analysts expect earnings to reach $41.0 million (and earnings per share of $1.46) by about September 2028, up from $-12.0 million today.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 12.1x on those 2028 earnings, up from -21.3x today. This future PE is lower than the current PE for the US Biotechs industry at 15.3x.
Analysts expect the number of shares outstanding to grow by 1.46% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.8%, as per the Simply Wall St company report.

Fennec Pharmaceuticals Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Fennec remains heavily dependent on a single commercial product (PEDMARK®); any clinical, regulatory, or market-based setbacks (such as adverse safety findings or competitive headwinds) with PEDMARK could have an outsized negative impact on revenue and earnings due to lack of product diversification.
The company's addressable market size may face plateauing growth as PEDMARK® approaches saturation in its approved indications and geographic regions; any delay, failure, or slow progress in expanding indications, pipeline development, or international approvals could limit future revenue growth and long-term top-line expansion.
Increasing global scrutiny and regulation of drug pricing, as highlighted by the pending final pricing processes in key EU markets (like Germany), introduce meaningful risk that Fennec may not be able to secure or maintain premium pricing abroad, putting downward pressure on revenue and net margins.
Competition from compounded alternatives, especially in academic centers for pediatric patients, and the potential for future generic or biosimilar entrants once patent protection or exclusivity periods lapse, could erode PEDMARK®'s market share and impact both revenues and margins over time.
The company's operating expense profile shows significant ongoing investment in commercialization, headcount, marketing, and intellectual property; if revenues do not scale as anticipated or milestone payments from partnerships (such as with Norgine or a potential Japan partner) are delayed or smaller than expected, Fennec may experience net losses, cash burn, and possible future dilutive capital raises, thereby pressuring long-term earnings and shareholder value.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $14.0 for Fennec Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $100.8 million, earnings will come to $41.0 million, and it would be trading on a PE ratio of 12.1x, assuming you use a discount rate of 6.8%.
Given the current share price of $9.22, the analyst price target of $14.0 is 34.1% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Fennec Pharmaceuticals?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Expanding Global Supportive Cancer Care Will Unlock Future Opportunities